Patent ID: 8609628

Claim:
A method of treating a subject who has, or is at increased risk of developing chronic obstructive pulmonary disease, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula: wherein R is C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 1 -C 12 alkyl esters, C 1 -C 12 alkyl amides, C 4 -C 12 alkenyl esters, C 1 -C 12 alkylaryl esters, C 4 -C 12 alkenylaryl esters, C 4 -C 12 alkenyl amides, C 1 -C 12 alkoxy, formylC 1 -C 12 alkyl, formylC 2 -C 12 alkenyl, alkanoylC 1 -C 12 alkyl, alkanoylC 2 -C 12 alkenyl, carboxyC 1 -C 12 alkyl, carboxyC 2 -C 12 alkenyl, wherein the alkyl and alkenyl groups are optionally substituted with 1-6 substituent groups selected from the group consisting of: C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, aryl, heteroaryl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, C 2 -C 6 alkenyl, OH, nucleosides, nucleotides, aromatic esters, aryl esters, cycloalkyl esters, cycloalkenyl esters, purines, or pyrimidines; OR 1 is OH or —O(CO)CH 3 ; R 2 is —CH═CHCH═CH 2 , —CH 2 -phenyl, or —CH 2 -pyridyl, wherein the phenyl and pyridyl groups are optionally substituted at each substitutable position with a group that is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, halogen, —CO 2 H, C 1 -C 6 alkoxycarbonyl, —C(O)NH 2 , —C(O)NH(C 1 -C 6 alkyl), or —C(O)N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl); or a pharmaceutically acceptable salt, solvate, ester, amide, or hydrate thereof.